Newest studies

Dementia classification using two-channel electroencephalography features

43/100 ✓ Peer-reviewed Cognitive tests and assessment Scientific Reports

Key finding: Significant differences were observed in peak frequency (PF), alpha (A), theta (T), the ratio of alpha to theta (A/T), the ratio of alpha to low-beta (A/BL), and coherence (CH) between patients and NCs. +1 more finding

• Diagnosis

Full summary, score breakdown and related studies → Original source

Evaluating the diagnostic performance of six plasma biomarkers for Alzheimer’s disease and other neurodegenerative dementias in a large Chinese cohort

56/100 ✓ Peer-reviewed How common it is Alzheimer s Research & Therapy

Key finding: Plasma p-tau217 and p-tau231 were most effective in diagnosing aMCI/AD (AUC = 0.95 and 0.93, respectively), while p-tau217, p-tau231 and p-tau181 presented the best differential diagnosis for AD from PSP, FTD and DLB respectively (AUC = 0.84, 0.81 and 0.83). α-synuclein was presented as the best biomarker for PSP variant and behavior variant FTD subtypes (AUC = 0.81 and 0.74, respectively). +4 more findings

• Biomarkers
• Diagnosis

Full summary, score breakdown and related studies → Original source

Immune and metabolic effects of African heritage diets versus Western diets in men: a randomized controlled trial

72/100 ✓ Peer-reviewed Prevention and risk Nature Medicine

Key finding: The switch from heritage-style to Western-style diet affected different metabolic pathways associated with noncommunicable diseases and promoted a pro-inflammatory state with impaired whole-blood cytokine responses to microbial stimulation. +1 more finding

• Clinical Trials
• Lifestyle

Full summary, score breakdown and related studies → Original source

Down syndrome and Alzheimer's disease: Oxidative stress in the neurodegenerative process

39/100 ✓ Peer-reviewed Down syndrome and Alzheimer's Journal of Alzheimer's disease : JAD

Key finding: The activity of GPx was similar between the groups, as well as MDA and HNE.ConclusionThe results suggest that alterations of the antioxidative processes can be implicated in the onset of neurodegeneration observed in individuals with DS.

• Down Syndrome
• Brain Biology

Full summary, score breakdown and related studies → Original source

Are Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Central Nervous System (CNS) Penetrant: A Narrative Review

43/100 ✓ Peer-reviewed Drug development Neurology and therapy

Key finding: We identified 14 studies that were included in this synthesis. +3 more findings

Full summary, score breakdown and related studies → Original source

Inhibition of tau neuronal internalization using anti-tau single domain antibodies

46/100 ✓ Peer-reviewed Drug development Nature communications

Key finding: A31 and Z70mut1 bind to microtubule binding domain repeats, which are involved in the interaction with LRP1. +4 more findings

Full summary, score breakdown and related studies → Original source

Cross-ancestry genome-wide association study identifies implications of SORL1 in cerebral beta-amyloid deposition

79/100 ✓ Peer-reviewed Genetics Nature communications

Key finding: Our GWAS analysis replicates known loci (APOE4, CR1, and FERMT2) and identifies a novel locus near SORL1 that is significantly associated with β-amyloid deposition. +1 more finding

• Genetics
• Brain Biology

Full summary, score breakdown and related studies → Original source

A real-world disproportionality analysis of FDA adverse event reporting system (FAERS) events for lecanemab

53/100 ✓ Peer-reviewed Treatments Frontiers in pharmacology

Key finding: Recent Phase 3 clinical trials have demonstrated its ability to reduce brain amyloid-β (Aβ) load and slow cognitive decline in patients with early Alzheimer's disease (AD). +3 more findings

• Treatments
• Clinical Trials
• Side Effects

Full summary, score breakdown and related studies → Original source

Alzheimer's disease blood-based biomarker testing: A stakeholder-informed assessment of coverage considerations

37/100 ✓ Peer-reviewed Health systems and care delivery Journal of Alzheimer's disease : JAD

Key finding: BackgroundRecently published clinical studies suggest that blood-based biomarker tests (BBMTs) for Alzheimer's disease (AD) provide value, but in the U.S., neither public nor private payers currently cover these tests.

• Biomarkers
• Policy
• Health Equity

Full summary, score breakdown and related studies → Original source

A meta-review and synthesis of the effectiveness of psychosocial interventions for people living with dementia nearing the end of life and their family carers

58/100 ✓ Peer-reviewed End-of-life care International Psychogeriatrics

Key finding: Thirty-four reviews were included, published between 2009 and 2023. +4 more findings

• Caregiving
• End-of-Life Care

Full summary, score breakdown and related studies → Original source

Ethics of Sensor-Based Surveillance of People with Dementia in Clinical Practice

42/100 ✓ Peer-reviewed Clinical safety Sensors

Key finding: In this discussion paper, we provide a brief overview of frequently used SST and discuss ethical issues associated with their use.

• Digital Tools
• Care Services

Full summary, score breakdown and related studies → Original source

Mechanisms of action of formononetin, an extract from Astragalus membranaceus medicinal plant, in ameliorating Alzheimer’s disease

34/100 ✓ Peer-reviewed Disease mechanisms Exploration of neuroscience

Key finding: Additionally, formononetin might inhibit the Aβ/RAGE interaction which further inactivates the activity of extracellular signal regulated kinase (ERK), Janus kinase (JNK) signaling pathway that results in the reduction of nuclear translocation of nuclear factor kappa B (NF-κB) and also reduces the cytokines level to ameliorate AD.

• Brain Biology

Full summary, score breakdown and related studies → Original source

Characterization of brain morphology associated with metabolic dysfunction‐associated steatotic liver disease in the UK Biobank

51/100 ✓ Peer-reviewed Long-term cohort studies Diabetes Obesity and Metabolism

Key finding: MASLD was significantly associated with smaller volumes of total grey matter and subcortical grey matter (p < 0.05) and reduced Alzheimer's disease (AD)-signature cortical thickness (multivariable-adjusted β = -0.04; 95% confidence interval [CI]: -0.07, -0.01). +3 more findings

Full summary, score breakdown and related studies → Original source

Effects of 52 weeks of precuneus rTMS in Alzheimer’s disease patients: a randomized trial

57/100 ✓ Peer-reviewed Cognitive tests and assessment Alzheimer s Research & Therapy

Key finding: Repetitive TMS of the PC (PC-rTMS) had a significant effect on the primary outcome measure. +2 more findings

• Clinical Trials

Full summary, score breakdown and related studies → Original source

Does Midbrain Atrophy Distinguish Progressive Supranuclear Palsy from Frontotemporal Dementia?

42/100 ✓ Peer-reviewed Lewy body dementia Movement Disorders Clinical Practice

Key finding: Compared to controls, PSP and bvFTD had lower values of midbrain area, HBS-RS and GMA, and higher MRPI and MRPI 2.0. +2 more findings

• Other Dementias

Full summary, score breakdown and related studies → Original source

Aging, mitochondrial dysfunction, and cerebral microhemorrhages: a preclinical evaluation of SS-31 (elamipretide) and development of a high-throughput machine learning-driven imaging pipeline for cerebromicrovascular protection therapeutic screening

43/100 ✓ Peer-reviewed Digital health tools GeroScience

Key finding: While SS-31 treatment did not significantly mitigate hypertension-induced CMH burden in aged mice, our high-throughput imaging pipeline provided a reliable, scalable, and unbiased approach to CMH detection, reducing processing time while improving accuracy. +1 more finding

• Brain Biology
• Digital Tools
• Treatments

Full summary, score breakdown and related studies → Original source

Treatment of Restless Legs Syndrome Improves Agitation and Sleep in Persons with Dementia: A Randomized Trial

65/100 ✓ Peer-reviewed Disparities Journal of the American Medical Directors Association

Key finding: Most were female (72.0%), white (92.3%), non-Hispanic (84.6%), and lived in nursing homes (76.9%). +4 more findings

• Clinical Trials
• Lifestyle

Full summary, score breakdown and related studies → Original source

The significance of a dementia diagnosis from the perspective of the family caregivers: a qualitative study

38/100 ✓ Peer-reviewed Getting a diagnosis BMC Health Services Research

Key finding: Three main categories were created: (1) Impact of observed cognitive decline, (2) Impact of diagnosis on service engagement, and (3) Support and follow-up for family caregivers. +4 more findings

• Caregiving
• Diagnosis

Full summary, score breakdown and related studies → Original source

A natural experiment on the effect of herpes zoster vaccination on dementia (Wales)

74/100 ✓ Peer-reviewed Prevention and risk Nature

Key finding: We successfully confirm our findings in a different population (England and Wales's combined population), with a different type of data (death certificates) and using an outcome (deaths with dementia as primary cause) that is closely related to dementia, but less reliant on a timely diagnosis of dementia by the healthcare system 10 .

• Prevention

Full summary, score breakdown and related studies → Original source

Modified titration of donanemab reduces ARIA risk and maintains amyloid reduction

76/100 ✓ Peer-reviewed Clinical trials Alzheimer's & Dementia

Key finding: Gradual up-titration of dose significantly reduced ARIA-E risk while demonstrating comparable pharmacokinetics/pharmacodynamics compared to standard dosing. +4 more findings

• Clinical Trials
• Side Effects
• Treatments

Full summary, score breakdown and related studies → Original source

Treatment-resistant late-life depression prevalence and clinical/sociodemographic correlates: An electronic health records study

75/100 ✓ Peer-reviewed Risk factors Journal of affective disorders

Key finding: Of 8171 patients with late-life depression, 1443 (17.7 %) had TRLLD. +4 more findings

• Treatments

Full summary, score breakdown and related studies → Original source

Japanese participant data from three gantenerumab trials in early Alzheimer's disease

89/100 ✓ Peer-reviewed Treatments Alzheimer's & dementia : the journal of the Alzheimer's Association

Key finding: Slowing of cognitive and functional decline, and amyloid reduction in gantenerumab group compared to placebo group were greater in Japanese-GRADUATE than in the global-GRADUATE and JP40959. +4 more findings

• Clinical Trials

Full summary, score breakdown and related studies → Original source

Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial

83/100 ✓ Peer-reviewed Treatments The Lancet. Neurology

Key finding: Of 74 participants who were recruited into the OLE study between June 3, 2020, and April 22, 2021, 73 were enrolled and received gantenerumab treatment. 47 (64%) stopped dosing due to early termination of the study by the sponsor, and 13 (18%) prematurely discontinued the study for other reasons; 13 people completed 3 years of treatment. +4 more findings

• Clinical Trials
• Treatments
• Side Effects

Full summary, score breakdown and related studies → Original source

APOE4 impairs autophagy and Aβ clearance by microglial cells

43/100 ✓ Peer-reviewed Genetics Inflammation research : official journal of the European Histamine Research Society ... [et al.]

Key finding: In sporadic AD and in families with higher risk of AD, correlation with apolipoprotein E4 (APOE) allele expression has been found. +4 more findings

• Brain Biology
• Genetics

Full summary, score breakdown and related studies → Original source

A real-world pharmacovigilance study of adverse drug reactions associated with lecanemab and aducanumab based on WHO-VigiAccess and FAERS databases

50/100 ✓ Peer-reviewed Treatments Frontiers in pharmacology

Key finding: This study compared the ADRs of Lecanemab and Aducanumab, revealing that ARIA was the most common AE for both drugs. +4 more findings

• Treatments
• Side Effects

Full summary, score breakdown and related studies → Original source